Yousif Capital Management LLC Has $1.21 Million Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Yousif Capital Management LLC raised its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 3.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 54,953 shares of the company’s stock after buying an additional 1,872 shares during the quarter. Yousif Capital Management LLC’s holdings in Teva Pharmaceutical Industries were worth $1,211,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. DAVENPORT & Co LLC lifted its position in shares of Teva Pharmaceutical Industries by 3.8% in the 4th quarter. DAVENPORT & Co LLC now owns 381,488 shares of the company’s stock valued at $8,408,000 after acquiring an additional 13,811 shares in the last quarter. Capital Insight Partners LLC increased its holdings in shares of Teva Pharmaceutical Industries by 190.1% in the 4th quarter. Capital Insight Partners LLC now owns 40,617 shares of the company’s stock valued at $895,000 after purchasing an additional 26,617 shares during the period. Robeco Institutional Asset Management B.V. lifted its position in shares of Teva Pharmaceutical Industries by 7.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock worth $10,983,000 after purchasing an additional 33,277 shares in the last quarter. Genesee Capital Advisors LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 12.5% during the fourth quarter. Genesee Capital Advisors LLC now owns 15,028 shares of the company’s stock worth $331,000 after purchasing an additional 1,664 shares during the period. Finally, KBC Group NV boosted its holdings in shares of Teva Pharmaceutical Industries by 43.2% during the fourth quarter. KBC Group NV now owns 37,163 shares of the company’s stock worth $819,000 after purchasing an additional 11,220 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Up 1.5 %

Shares of TEVA opened at $16.59 on Friday. The business’s fifty day moving average price is $20.01 and its two-hundred day moving average price is $18.50. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.61 and a current ratio of 0.98. The firm has a market capitalization of $18.79 billion, a price-to-earnings ratio of -11.44, a PEG ratio of 1.39 and a beta of 0.71. Teva Pharmaceutical Industries Limited has a 52 week low of $12.51 and a 52 week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, analysts predict that Teva Pharmaceutical Industries Limited will post 2.62 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on the company. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. JPMorgan Chase & Co. boosted their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Barclays decreased their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. UBS Group lowered their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Finally, Piper Sandler raised their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $23.57.

Insider Transactions at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. This represents a 30.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now directly owns 695,000 shares of the company’s stock, valued at $15,296,950. This represents a 29.15 % decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.